Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer

Author(s): Nadia Caccamo, Serena Meraviglia, Giuseppe Cicero, Gaspare Gulotta, Francesco Moschella, Adriana Cordova, Eliana Gulotta, Alfredo Salerno, Francesco Dieli

Journal Name: Current Medicinal Chemistry

Volume 15 , Issue 12 , 2008

Become EABM
Become Reviewer


Several observations in mice and in humans have collectively laid the foundation for examining the potential of γ δ T cells to exert tumor immunotherapy. Human γ δ T cells can be activated in a non-MHC dependent fashion either by low molecular mass phosphoantigens, or by agents that provoke the accumulation of endogenous pyrophosphates such as isopentenylpyrophosphate. Among the latter, aminobisphosphonates are well-established in the clinic, and extensive data are available on the compounds antiangiogenic, antiosteolytic and pro-apoptotic properties. In this review we discuss on the possibility that the intentional activation of γ δ T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in patients with different types of cancer.

Keywords: Human γ δ T cells, tumors, phosphoantigens, bisphosphonates, immunotherapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [1147 - 1153]
Pages: 7
DOI: 10.2174/092986708784310468
Price: $65

Article Metrics

PDF: 5